ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

Clinical trials for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT explained in plain language.

Never miss a new study

Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT trials appear

Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 1

New cell therapy takes on Epstein-Barr virus in patients with weak immune systems

Disease control Ongoing

This study tests an experimental cell therapy called tabelecleucel in about 190 people with diseases caused by the Epstein-Barr virus (EBV). The treatment uses specially trained immune cells to attack EBV-infected cells. The main goal is to see if the therapy can shrink tumors or…

Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated May 17, 2026 07:31 UTC

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT

Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT trials appear

New cell therapy takes on Epstein-Barr virus in patients with weak immune systems